Tiziana Life Sciences
TLSA
About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Employees: 9
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
24% more capital invested
Capital invested by funds: $3.25M [Q1] → $4.03M (+$781K) [Q2]
1.19% more ownership
Funds ownership: 2.71% [Q1] → 3.9% (+1.19%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
9% less funds holding
Funds holding: 32 [Q1] → 29 (-3) [Q2]
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Financial journalist opinion
Based on 4 articles about TLSA published over the past 30 days